550 - Vitiligo is associated with new onset osteoporosis: a population-based study
Naama Tova Cohen,Nanette B Silverberg,Khalaf Kridin
DOI: https://doi.org/10.1093/bjd/ljad498.071
IF: 11.113
2024-02-01
British Journal of Dermatology
Abstract:Abstract Introduction/Background Vitiligo, an autoimmune disease leading to skin depigmentation, affects about 2% of the global population. The current pathogenesis for vitiligo is the autoimmune theory; recent reports demonstrated the role of pro-inflammatory cytokines in vitiligo. Osteoporosis is an inflammatory condition, characterized by elevated pro-inflammatory cytokines, associated with increased bone metabolism. The association between osteoporosis and vitiligo has never been investigated in a cohort study. We aimed to investigate if patients with vitiligo are at increased risk for developing osteoporosis. Methods A retrospective, cohort study was conducted on the Clalit Health Services (CHS) database (2002-2019) exploring age, sex, ethnicity, comorbidities, and Charlson comorbidity index. Results 19,985 vitiligo patients, and 99,003 controls, mean age 33.2 (SD +/-21.6) years were included. The incidence rates (95%CI) of new-onset osteoporosis were 2.6 (2.3-2.9)/1,000 person-years (PY) in vitiligo patients and 2.2 (2.1-2.3)/1,000PY in the control group. In multivariate analysis adjusted for age, sex, ethnicity, smoking, obesity, hyperlipidemia, diabetes mellitus, and hypertension, the hazard ratio (95% CI) for new-onset osteoporosis in patients with vitiligo was 1.19 (1.04-1.38, p-value 0.006). In vitiligo patients, the odds ratio (95%CI) for osteoporosis were 2.05 (1.91-2.21, p-value <0.001), female sex 4.04 (3.03-5.38, p-value 0.001), Jewish ethnicity 3.65 (2.45-5.44, p-value <0.001), hypertension 5.02 (3.96-6.36, p-value <0.001), hyperlipidemia 6.99 (5.37-9.08, p-value <0.001), obesity 1.34 (1.02-1.76, p-value-0.036) and diabetes mellitus 3.56 (2.74-4.62, p-value <0.001). Conclusions In the current study we observed an increased risk of developing osteoporosis in patients with vitiligo. Our observation merits further study and highlights the systemic aspect of inflammation in vitiligo.
dermatology